Health Care · Biological Products, (No Diagnostic Substances) · Nasdaq · CIK 1980845 · FYE Oct 31 · Prices AT CLOSE 2026-08-21 (USD) Last $1.78 · Day +0.56% · Mkt cap $119M · 1Y −54.5% · Off 52W high −85.5% · Vol (1Y) 123.2% Price2023-11-01 → 2026-08-21 ENGN close: $20.0 on 2023-11-01 to $1.8 on 2026-08-21. Split-adj closes · 240 of 699 · price returnⓘ At a glance | Short interest2.6% of sh out | | Days to cover2.5d | | Top-10 13F concentration100.0% | | Next report (est.)2026-09-15 |
SI 2026-07-31 · 13F 2026-Q1ⓘ Key fundamentalsFY 2025 | Earnings (TTM)-$126.8M | | ROE−53.3% | | ROIC−89.6% |
FY ratios · TTM sales/earnings (USD)ⓘ Trailing returns | YTD−80.3% | | 1Y−54.5% | | Since incept. (ann.)−57.8% |
Total return · from 2023-11-01ⓘ Risk | Ann. volatility (1Y)123.2% | | Ann. volatility (3Y)131.0% | | Sharpe (1Y)0.37 | | Sharpe (3Y)0.03 | | Max drawdown (1Y)−88.2% | | Max drawdown (3Y)−92.8% | | Beta (3Y vs SPY)1.67 |
Daily returns, ann.ⓘ Top institutional holders13F 2026-Q1 | Manager | Shares | Value | % sh out | QoQ |
|---|
| MARSHALL WACE, LLP | 343,928 | $2M | 0.51% | new | | SBI Securities Co., Ltd. | 28 | $191 | 0.00% | new |
Δ vs 2025-Q4ⓘ Latest reported quarterslast report 2026-06-15 | Period end | Reported | EPS | EPS YoY | Revenue | Rev YoY |
|---|
| 2026-04-30 | 2026-06-15 | −$0.43 | — | — | — | | 2026-01-31 | 2026-03-09 | $0.44 | −8.3% | — | — | | 2025-07-31 | 2025-09-11 | $0.57 | +78.1% | — | — | | 2025-04-30 | 2025-06-12 | −$0.51 | −234.2% | — | — |
As-reported XBRL · next 2026-09-15 est.ⓘ Basis & disclosures - EOD closes · nothing imputed or averaged · absent “—”
- As-of differs by block · 13F = US long, 45+d lag, LOWER bound
- Not investment advice · no recommendation, price target or solicitation
- EDGAR + foreign registers · marketstack (licensed EOD) · spzco.com/methodology
| 
